You are here: Home »

Hair Loss

Category Archives: Hair Loss

Buy Rogaine online

Discount 10%: 879981.

Buy Rogaine(2%, 5%) online.

>>>> Buy now Rogaine 2% <<<<

Rogaine 2% is used to treat male pattern baldness in patients who are experiencing gradually thinning hair on the top of the head.

>>>> Buy now Rogaine 5% <<<<

Rogaine 5% is used to treat male pattern baldness in patients who are experiencing gradually thinning hair on the top of the head.

Rogaine: instructions for use and reviews.

Clinical and pharmacological group
The drug for the treatment of alopecia in men and women.

Active substance

Release form, composition and packaging
  Foam for external use 5% from white to yellowish-white in color, preserving the structure during the observation period of one minute.

Excipients: anhydrous ethanol – 536.3 mg, purified water – 314.1 mg, butylhydroxytoluene – 0.9 mg, lactic acid – 10 mg, anhydrous citric acid – 1 mg, glycerol – 20 mg, cetyl alcohol – 11 mg, stearyl alcohol – 5 mg, polysorbate 60 – 4 mg, propellant – propane / n-butane / isobutane% 48:30:22 – 50.2 mg.

  • 60 g – aluminum cylinders with a valve with a spray and a cap with a child protection system – polymer packaging.
    – the actual amount of minoxidil, without propellant, is 50 mg / g;
    – the actual amount of butylhydroxytoluene, without propellant, is 1 mg / g.

Pharmachologic effect
Being a peripheral vasodilator, minoxidil, when applied topically, enhances microcirculation in the area of ​​hair follicles. It stimulates the vascular endothelial growth factor, which is supposed to be responsible for the increase in capillary permeability, which indicates a high metabolic activity observed in the anagen phase.

Minoxidil stimulates hair growth in patients with hereditary hair loss (androgenic alopecia) in the initial and moderate stages. The exact mechanism of action of minoxidil for external use in hair loss is not fully understood.


When applied externally on intact skin, approximately 1–2% minoxidil solution undergoes systemic absorption.

In a clinical study, systemic absorption of 5% foam for external use was approximately half that of systemic absorption of a 5% solution for external use. The average values ​​of AUC0–12 h and Cmax with 5% foam were 8.81 ng × h / ml and 1.11 ng / ml, respectively, which corresponds to approximately 50% of the same values ​​when using 5% solution (18.71 ng × h / ml and 2.13 ng / ml, respectively).

Tmax with 5% foam is 5.42 hours and is similar to that with 5% solution (5.79 hours). The effect of minoxidil on hemodynamics is not expressed until the average serum concentration of minoxidil reaches 21.7 ng / ml.


Although it was previously reported that minoxidil does not bind to plasma proteins, its reversible binding to human plasma proteins in the range of 37–39% was later demonstrated by in vitro ultrafiltration.

Since only 1–2% of topically applied minoxidil is absorbed, the degree of binding to plasma proteins observed in vivo after topical application will be clinically insignificant.

Vd of minoxidil after iv administration at a dose of 4.6 mg and 18.4 mg is 73.1 L and 69.2 L, respectively.


Approximately 60% of minoxidil absorbed after topical application is metabolized to form minoxidil glucuronide, mainly in the liver.


T1 / 2 minoxidil for external use averages 22 hours, compared with 1.49 hours for oral use. 97% of minoxidil and its metabolites are excreted by the kidneys and 3% through the intestines.

After discontinuation of the drug, approximately 95% of minoxidil, applied topically, is excreted within 4 days.


  • androgenic alopecia in men and women.
  • violation of the integrity of the skin of the head;
  • dermatoses of the scalp;
  • the simultaneous use of other drugs on the scalp;
  • pregnancy;
  • lactation (breastfeeding);
  • age up to 18 years;
  • age over 65;
  • Hypersensitivity to minoxidil or other components of the drug.

With caution, the drug should be prescribed to patients with cardiovascular diseases, arrhythmia, renal and liver failure.

The drug is intended for external use. Before using the drug Rogaine , the hair and skin of the scalp should be thoroughly dried.

For the effectiveness of the drug and its achievement of the hair follicles, it is important to apply the drug to the skin of the scalp, and not to the hair.

For men, 1 g (1/2 cap) of foam is applied 2 times / day (morning and evening) on ​​the affected areas of the scalp. Rogaine should not be used more often than once every 12 hours. The total daily dose should not exceed 2 g of the drug (100 mg of minoxidil).

For women, 1 g (1/2 cap) of foam is applied 1 time / day to the affected areas of the scalp. Do not use Rogaine more than 1 time / day. The daily dose should not exceed 1 g of the drug (50 mg of minoxidil).

Do not apply Rogaine to other parts of the body.

Balloon recommendations

  1. Rotate the cap so that the arrows on the spray gun and cap are aligned.
  2. Tilt the cap back and remove it.
  3. Before squeezing the foam, it is recommended that you first rinse your fingers with cold water and dry thoroughly, as Upon contact with warm skin, the foam may dissolve.
  4. Turning the can upside down, press the spray gun and squeeze the required amount of foam onto your fingers.
  5. Distribute the foam with your fingertips over the areas of baldness and gently rub into the skin of the scalp.
  6. After using Rogaine , put a cap on the bottle. To keep the packaging safe from accidental opening by children, make sure that the arrows on the spray gun and cap are not aligned.

After applying Rogaine , wash your hands thoroughly.

The appearance of the first signs of suspension of hair loss and restoration of hair growth is possible after the use of the drug Rogaine 2 times / day in men for 2–4 months and 1 time / day in women for 3–6 months.

To achieve and maintain the achieved effect of restoration of hair growth, the patient should not interrupt the use of the drug, otherwise hair loss will resume.

An increase in the dose of the drug or its more frequent use will not lead to an improvement in the results of therapy.

If after the use of the drug Rogaine in men for 16 weeks and in women for 24 weeks, there is no increase in hair growth, then the drug should be discontinued.

After you start using Rogaine, you may experience increased hair loss. This effect is caused by the influence of minoxidil. It is expressed in stimulating the transition of hair from the resting phase (telogen) to the growth phase (anagen). Thus, there is a loss of old hair, in the place of which new ones grow. Temporary enhancement of hair loss usually lasts for 2-6 weeks from the start of treatment, and then decreases for 2 weeks.

Side effects
The frequency of adverse reactions is given in the form of the following gradation: very often (≥1 / 10); often (≥1 / 100, <1/10); infrequently (≥1 / 1000, <1/100); rarely (≥1 / 10,000, <1/1000); very rarely (<1/10 000), including individual messages of unspecified frequency (frequency cannot be calculated from the available data).

Adverse events reported in clinical trials

From the nervous system: often – headache.

On the part of the skin and subcutaneous tissues: often – skin itching, rash; rarely – dermatitis, manifested in the form of redness, peeling and inflammation.

Post-marketing data

Allergic reactions: very rarely – angioedema (swelling of the lips, swelling of the tissues of the oral cavity, swelling of the oropharynx, swelling of the pharynx and swelling of the tongue), hypersensitivity (swelling of the face, generalized erythema, generalized skin itching, a feeling of tightness in the throat), allergic contact dermatitis.

From the nervous system: very rarely – dizziness, headache.

From the side of the organ of vision: very rarely – eye irritation.

From the cardiovascular system: very rarely – tachycardia, palpitations; infrequently – lowering blood pressure.

From the respiratory system: very rarely – shortness of breath.

From the digestive system: very rarely – nausea, vomiting.

On the part of the skin and subcutaneous tissues: very rarely – reactions at the place of use (these reactions can extend to the ears and face, include: itching, irritation, pain, rash, swelling, dry skin, erythema; however, in some cases, reactions may be more severe, including: exfoliation, dermatitis, blistering, bleeding, ulceration), temporary hair loss, hair color changes, violation of hair texture, hypertrichosis (unwanted hair growth outside the place of use).

Other: very rarely – peripheral edema, chest pain.

If any of the side effects indicated in the instructions are exacerbated or any other side effects not listed in the instructions are noted, the patient should be informed by the doctor.

If doses exceeding the recommended are applied to large areas of the body or other parts of the body, in addition to the scalp, an increase in systemic absorption of minoxidil is possible, which can lead to the development of adverse events.

Symptoms: unwanted effects on the part of the cardiovascular system associated with sodium and water retention, as well as tachycardia, decreased blood pressure and dizziness.

Treatment: symptomatic and supportive therapy. Beta-blockers can be prescribed for the treatment of tachycardia, diuretics are used to eliminate edema. In the event of a decrease in blood pressure, a 0.9% sodium chloride solution should be administered iv. Sympathomimetic agents, for example, epinephrine and norepinephrine, which have excessive pacemaking activity, should not be used.

Drug interaction
There is a theoretical possibility of enhancing orthostatic hypotension in patients receiving concomitant treatment with peripheral vasodilators, but without clinical confirmation.

It is impossible to exclude a very slight increase in the content of minoxidil in the blood of patients with arterial hypertension who are taking minoxidil inside, in case of simultaneous use of the drug Rogaine, although relevant clinical studies have not been conducted.

It has been established that minoxidil for external use can interact with some other drugs for external use.

For external use, minoxidil should not be used simultaneously with any other drugs (GCS, tretinoin, anthralin) applied to the skin of the scalp.

The simultaneous use of minoxidil in the form of a foam for external use and a cream containing betamethasone (0.05%) leads to a decrease in the systemic absorption of minoxidil.

The simultaneous use of a cream containing tretinoin (0.05%) leads to an increase in the absorption of minoxidil.

The simultaneous application of minoxidil and topical preparations, such as tretinoin and dithranol, to the skin, which cause changes in the protective functions of the skin, can lead to increased absorption of minoxidil.

Special instructions
Before starting treatment with Rogaine , it is necessary to conduct a general examination, including the collection and study of a medical history. The doctor should make sure that the scalp is healthy.

Apply the drug Rogaine only to healthy skin of the scalp. You can not use the drug for inflammation, infection, irritation, soreness of the skin, as well as simultaneously with other drugs applied to the skin of the scalp.

You should not use the drug Rogaine in cases of sudden hair loss, focal alopecia, when alopecia develops after childbirth, in case of baldness caused by taking medications, malnutrition (iron deficiency, vitamin A), as a result of hair styling in “tight” hairstyles, as well as when the cause of hair loss is unknown.

With a decrease in blood pressure or the appearance of chest pain, palpitations, weakness or dizziness, a sudden inexplicable increase in body weight, swelling of the hands or feet, persistent redness or irritation of the scalp, the patient should stop using Rogaine and consult a doctor.

Some components of the drug can cause burning and irritation. In case of contact with sensitive surfaces (eyes, irritated skin, mucous membranes), rinse the affected area with plenty of cool water. The drug contains butylhydroxytoluene, cetyl and stearyl alcohol, which can cause local skin reactions (for example, contact dermatitis).

Accidental ingestion of the drug can lead to the development of serious adverse events from the heart. Therefore, this drug should be stored in places inaccessible to children.

The contents of the container are under pressure. Do not pierce or burn the cylinder. The product is flammable, so do not spray the contents of the container near an open flame, polished or painted surfaces. Avoid contact with open flames during use, storage and disposal. Do not heat the cylinder above 50 ° C. When applying the drug should refrain from smoking.

If a medicine has fallen into disrepair or has expired, do not pour it into wastewater or throw it into the street. It is necessary to put the medicine in a bag and put in a garbage container. These measures will help protect the environment.

Recommendations for the use of the drug in conjunction with hair care products

The drug will not be effective when used:

  • a hair dryer after applying foam to the scalp;
  • hair care products that can cause scarring, as well as deep scalp burns;
  • methods of hair care that require strong pulling of hair from the scalp (for example, weaving “tight” braids (brading) or a ponytail hairstyle).

There is no need to wash your hair to apply the drug. If you wash your hair before using the medicine, you need to dry your hair and scalp.

When using hair styling products, you must first apply the foam and wait until it dries, and then use hair styling products.

Shampooing is allowed at least 4 hours after applying the drug.

There is no data on the effect of dyeing, perming, hair straighteners on the effectiveness of the drug. Because perming and staining can cause scalp irritation, the following precautions are recommended:

  • before staining and / or perm, it is necessary to make sure that the drug was washed off the hair and scalp in order to avoid possible irritation of the scalp;
  • for best results, do not apply the drug on the same day as the chemical treatment of the hair;
  • after using any chemicals, do not apply the drug for 24 hours to make sure that the scalp is not irritated after perming and / or staining.

Influence on the ability to drive vehicles and control mechanisms

In connection with the possible development of headache, dizziness, eye irritation, caution should be exercised when driving vehicles and practicing certain activities that require an increased concentration of attention and speed of psychomotor reactions. When the occurrence of the described adverse events should refrain from performing these activities.

Pregnancy and lactation
The drug Rogaine in the form of a foam is contraindicated in women during pregnancy and during breastfeeding.

Use in childhood
The drug is contraindicated for use in patients under the age of 18 years.

With impaired renal function
With caution, the drug should be prescribed to patients with renal failure.

With impaired liver function
With caution, the drug should be prescribed to patients with liver failure.

Use in old age
The drug is contraindicated for use in patients over the age of 65 years.

Terms and conditions of storage
The drug should be stored out of the reach of children at a temperature not exceeding 25 ° C. Shelf life is 3 years. Do not use the drug after the expiration date indicated on the package.

Buy Dutas online

Discount 10%.

>>> Buy now DUTAS <<<

Analogs of: Dutas Avodart.
Other names of Avodart: 

Avidart, Duagen, Duodart, Duprost, Dutasterid, Dutasterida, Dutasteridum, Zytefor.

Clinico-pharmacological group
Drug for the treatment of benign prostatic hyperplasia. An inhibitor of 5α-reductase.

Composition, structure and packing
Soft gelatin capsules, yellow, oblong, opaque, marked with the code * “GX CE2”.
1 caps. 500 mg dutas
Excipients: mono- and diglycerides of caprylic / capric acid – 349.5 mg BHT – 35 micrograms.
The composition of the capsule shell: gelatin – 144.8 mg, glycerol – 70.8 mg of titanium dioxide – 1.78 mg iron oxide yellow – 127 g, medium-chain triglycerides – qs, lecithin – qs, red ink for printing ** – qs
10 pieces. – Blisters (3) – packs cardboard.
10 pieces. – Blisters (9) – packs cardboard.
* Application code “GX CE2” in red ink used for printing in the manufacture of the finished dosage form production site Catalent France Beinheim SA (France); application code “GX CE2” gray with cold UV laser is used in the manufacture of the finished dosage form production site GlaxoSmithKline SA Rharmaceuticals (Poland).
** Red ink for printing used in the manufacture of the finished dosage form production site Catalent France Beinheim SA (France) and are not used in the manufacture of the finished dosage form production site GlaxoSmithKline SA Rharmaceuticals (Poland). The amount of ink in each capsule is less than 0.28 mg; materials remaining on the capsule are polyvinyl acetate phthalate, polyethylene glycol, propylene glycol, iron oxide red (E172, CI77491).

Pharmachologic effect
Drug for the treatment of benign prostatic hyperplasia. dutas – dual inhibitor of 5α-reductase. Inhibits the activity of 5α-reductase isozymes 1 and type 2, which is responsible for the conversion of testosterone to 5α-dihydrotestosterone (DHT). DHT is the primary androgen responsible for hyperplasia of glandular tissue of the prostate gland.
The maximum impact of dutas to reduce the concentration of DHT is dose dependent and is observed within 1-2 weeks after starting treatment. After 1 and 2 weeks dutas dose of 500 mg / day average dihydrotestosterone concentration in serum is reduced by 85% and 90%.

After a single dose of the drug in a dose of 500 mg of dutas serum Cmax is reached within 1-3 hours. The absolute bioavailability is about 60% relative to a 2-hour / infusion. The bioavailability of dutas is not dependent on food intake.

Pharmacokinetic data obtained after single and multiple dutas, Vd indicates a large (300 to 500 liters). dutas has a high degree of binding to plasma proteins (> 99.5%).
When taken daily dutas concentration in serum reaches 65% of the steady-state level after 1 month and approximately 90% of that level in 3 months. Stationary dutas concentration in serum (Css), equal to about 40 ng / ml, achieved after 6 months of daily administration of 500 micrograms of the drug. Sperm as serum, dutas stationary concentrations also reached after 6 months. After 52 weeks of treatment, dutas concentrations in semen averaged 3.4 ng / ml (range 0.4 to 14 ng / ml). From the serum in the sperm gets approximately 11.5% of dutas.

In vitro dutas is metabolized by CYP3A2 isoenzyme to form two small monogidroksilirovannyh metabolites; however, it does not apply isoenzymes CYP2C9, CYP1A2, CYP2A6, CYP2E1, CYP2C8, CYP2B6, CYP2C19 and CYP2D6. After reaching Css dutas, serum using mass spectrometric method exhibit unchanged dutas, 3 major metabolite (4′-gidroksidutasterid, 1,2-digidrodutasterid gidroksidutasterid and 6) and two small metabolite.

In humans, dutas is extensively metabolized. After oral administration in a daily dose of dutas 500 mg to achieve Css from 1% to 15.4% (average 5.4%) of the dose is excreted through the intestines unchanged. The remaining part is excreted in the form of four major metabolites, constituting 39%, 21%, 7% and 7%, respectively, and 6 small metabolites (the share of each of which is less than 5%).
After a person has kidney excreted trace amounts of unchanged dutas (less than 0.1% of the dose).
When receiving therapeutic doses of dutas its final T1 / 2 of 3-5 weeks.
dutas is detected in serum (at concentrations greater than 0.1 ng / ml) up to 4-6 months after discontinuation.

Linearity / non-linearity
Pharmacokinetics dutas can be described as a process of first order absorption and elimination of the two parallel processes, a saturated (m. E. Depending on concentration) and one saturable (m. E. Does not depend on the concentration). At low concentrations in serum (less than 3 ng / ml) dutas rapidly excreted via elimination of two processes. After receiving a single dose of 5 mg or less, dutas is rapidly eliminated from the body and has a short half-life equal to 3-9 days.
At concentrations in serum above 3 ng / ml is slower clearance of dutas (0.35-0.58 l / h), primarily through the unsaturated linear process of elimination with the final T1 / 2 of 3-5 weeks. At therapeutic concentrations, against a background of daily intake of 500 micrograms prevails slower clearance of dutas; total clearance is linear and concentration-dependent character.

Older men
Pharmacokinetics and pharmacodynamics of dutas were studied in 36 healthy men aged 24 to 87 years after a single dose (5 mg) of the drug. Between the different age groups was not statistically significant differences in pharmacokinetic parameters such as AUC and Cmax. There were no statistically significant differences in the values of T1 / 2 of dutas men between the age groups 50-69 years and above 70 years, which includes the majority of men with benign prostatic hyperplasia.
Between different age groups had no significant differences in the degree of reducing the levels of DHT. These results demonstrate the absence of the need to reduce the dose of dutas in elderly patients.

The drug can be taken regardless of meals.
The capsules should be swallowed whole, do not chew and do not open, because the contents of the capsule may cause irritation of the mucous membrane of the oropharynx.
Benign prostatic hyperplasia (BPH)
Adult males (including the elderly) The recommended dose of Avodart drug – 1 capsule (500 mg) 1 time / day. The capsules should be taken as a whole.
While improved during treatment with the drug comes pretty quickly, treatment should continue for at least 6 months in order to objectively evaluate the therapeutic effect.
For the treatment of BPH drug Avodart may be appointed as a monotherapy or in combination with alpha 1-blockers.
Special groups of patients
When receiving 500 mg / day via the kidneys excrete less than 0.1% of the dose, so there is no need to reduce the dose in patients with impaired renal function.
There is currently no data on the use of the drug Avodart in patients with impaired hepatic function. Because dutas is extensively metabolized and its half-life of 3-5 weeks, caution should be exercised in treating patients with drug Avodart impaired liver function.

When assigning dutas to 40 mg / day once (up to 80 times higher than the therapeutic dose) for 7 days, significant side effects were noted. In clinical studies, patients within 6 months dutas received 5 mg daily, with no additional side-effects to those observed in patients receiving 500 mg of dutas, have been discovered.
dutas no specific antidote, so if you suspect an overdose quite symptomatic and supportive care.

Drug Interactions
In vitro dutas is metabolized by CYP3A4 isoenzyme cytochrome P450 enzyme system. In the presence of inhibitors of CYP3A4 dutas concentration in the blood can increase.
With simultaneous use of dutas with CYP3A4 inhibitors verapamil and diltiazem there is a decrease in clearance of dutas. However, amlodipine, another calcium channel blocker, does not reduce the ground clearance of dutas. The reduction in clearance of dutas and the subsequent increase in its concentration in the blood, while the use of this drug and CYP3A4 inhibitors is not significant due to the wide range of security boundaries dutas, so there is no need to reduce the dose.
In vitro dutas is not metabolized following cytochrome P450 isozymes person: CYP1A2, CYP2A6, CYP2E1, CYP2C8, CYP2C9, CYP2C19 and CYP2D6.
dutas does not inhibit the enzyme in vitro system of human cytochrome P450 involved in the metabolism of drugs.
In vitro dutas does not displace warfarin, acenocoumarol, phenprocoumon, diazepam and phenytoin from their binding sites to plasma proteins, and these drugs are, in turn, do not displace dutas.
When conducting studies of the interaction of dutas with tamsulosin, terazosin, warfarin, digoxin and kolestiraminom a person of any clinically significant pharmacokinetic or pharmacodynamic interactions were observed.
In the application of dutas in conjunction with lipid-lowering drugs, ACE inhibitors, beta-blockers, calcium channel blockers, corticosteroids, diuretics, NSAIDs, inhibitors of phosphodiesterase type 5 and quinolone antibiotics any significant drug interactions were observed.

Pregnancy and lactation
Effects on fertility
Effect of dutas in a daily dose of 500 micrograms of sperm characteristics was studied in healthy volunteers aged 18-52 years. By 52 weeks of treatment the mean percent reduction in total sperm count, semen volume and sperm motor activity were 23%, 26% and 18% respectively compared to baseline. The concentration of spermatozoa and their morphological characteristics do not change.
After 24 weeks of observation of the average value of the percentage change in total sperm count in the group of dutas remained 23% lower compared to the baseline. The average value for all semen parameters at all time points remained within the normal range and did not meet the criteria for a clinically significant change (30%) at the 52 th week of treatment in two volunteers in a group of dutas total sperm count was reduced by more than 90% of Compared with baseline, with partial recovery at the 24 week follow-up.
Therefore, the clinical significance of the effect of dutas on the performance of individual sperm and fertility of the patient is unknown.

dutas is contraindicated in women. dutas was not studied in women because Preclinical data suggest that inhibition of DHT levels can cause inhibition of the development of the external genitalia of the fetus.

No data on the penetration of dutas passes into breast milk.

Side effects
Adverse events reported below are listed according to the anatomical and physiological classification and frequency of occurrence. The frequency of occurrence is defined as follows: very common (≥1 / 10), commonly (≥1 / 100 and <1/10), uncommon (≥1 / 1000 and <1/100), rarely (≥ 1/10 000 and < 1/1000), very rare (<1/10 000, including isolated cases). Frequency categories were formed on the basis of clinical studies and post-marketing drug surveillance.
The incidence of adverse events, formed the basis of post-marketing surveillance at.

On the part of the immune system
Very rarely allergic reactions (including rash, pruritus, urticaria, localized edema) and angioedema
Skin and subcutaneous fat
Rarely, alopecia (hair loss mainly on the body), or hypertrichosis
Mental Disorders
Very rarely, depression
Reproductive system
Very rarely testicular pain, testicular swelling
The incidence of adverse events, formed on the basis of clinical trial data (adverse events related to the use of dutas monotherapy)
In the third phase, placebo-controlled trials with dutas compared with placebo, the researchers evaluated adverse events associated with taking dutas:
Adverse events of adverse events in the 1st year of application of adverse events in the 2nd year of application
(n = 2158) dutas
(n = 2167) Placebo
(n = 1736) dutas
(n = 1744)
Erectile disfunktsiya2 3% 6% 1% 2%
Reduced libido2 2% 4% <1% <1%
Violation eyakulyatsii2 <1% 2% <1% <1%
Violations by zhelez1 infants <1% 1% <1% 1%
1 – including pain and breast enlargement.
2 – adverse effects from the reproductive system and mammary glands associated with the use of dutas (as monotherapy or in combination with tamsulosin). These adverse effects may persist after cessation of treatment and the effect of dutas on data retention adverse events is unknown.
Adverse events associated with the use of dutas in combination with tamsulosin
The following adverse events were reported in the study CombAT (comparison of dutas and tamsulosin 500 mg 400 mg 1 time / day as monotherapy or in combination for four years) and evaluated by researchers from the cumulative effect of ≥1%).
Adverse events of adverse events during the period of application of tamsulosin in combination with dutas
1st year 2nd year 3rd year 4th year
Kombinatsiya1 (n) (n = 1610) (n = 1428) (n = 1283) (n = 1200)
dutas (n = 1623) (n = 1464) (n = 1325) (n = 1200)
Tamsulosin (n = 1611) (n = 1468) (n = 1281) (n = 1112)
Erectile disfunktsiya3
A combination of 6% 2% <1% <1%
dutas 5% 2% <1% <1%
Tamsulosin 3% 1% <1% <1%
Reduced libido3
The combination of 5% <1% <1% 0%
dutas 4% 1% <1% 0%
Tamsulosin 2% <1% <1% <1%
Violation eyakulyatsii3
The combination of 9% 1% <1% <1%
dutas 1% <1% <1% <1%
Tamsulosin 3% <1% <1% <1%
Violations of the thoracic zhelez2
The combination of 2% <1% <1% <1%
dutas 2% 1% <1% <1%
Tamsulosin <1% <1% <1% 0%
The combination of 1% <1% <1% <1%
dutas <1% <1% <1% <1%
Tamsulosin 1% <1% <1% 0%
1 – = combination of dutas 500 mg 1 time / day + tamsulosin 400 mg 1 time / day;
2 – including pain and breast enlargement;
3 – adverse effects from the reproductive system and mammary glands associated with the use of dutas (as monotherapy or in combination with tamsulosin). These adverse effects may persist after cessation of treatment. Effect of dutas on data retention adverse events is unknown.

Conditions and terms
The drug should be stored out of reach of children at or above 30 ° C. Shelf life – 4 years.
– As monotherapy for the treatment and prevention of the progression of benign prostatic hyperplasia by reducing its size, relief of symptoms, improved urination, reduce the risk of acute urinary retention and the need for surgical intervention;
– As a combination therapy with alpha 1-blockers for the treatment and prevention of the progression of benign prostatic hyperplasia by reducing its size, alleviation of symptoms, improvement of urination, decrease the risk of acute urinary retention and the need for surgical intervention. Mainly I studied the combination of dutas and tamsulosin alpha1-blocker.

– Hypersensitivity to dutas, and other ingredients;
– Hypersensitivity to other inhibitors of 5α-reductase.
Avodart is contraindicated in women and children.
Precautions should be prescribed the drug for liver failure.

Special instructions
dutas is absorbed through the skin, so women and children should avoid contact with damaged capsules. In case of contact with damaged capsules should immediately rinse the appropriate site with soap and water.
Abnormal liver function
There is currently no data on the use of the drug Avodart in patients with impaired hepatic function. Because dutas is extensively metabolized and its half-life of 3-5 weeks, caution should be exercised in treating patients with drug Avodart impaired liver function.
Heart failure is the combined use of dutas and tamsulosin
The two 4-year clinical trials, the incidence of heart failure was higher in patients treated with the combination of dutas and alpha1-adrenergic blocker, primarily tamsulosin, than patients who had not received the combined treatment. In these two studies, the incidence of heart failure has remained low (≤ 1%) with some variability in between. But overall performance discrepancies frequency side effects of the cardiovascular system were noted. A causal relationship between treatment with dutas (alone or in combination with alpha1-blocker) and the development of heart failure has been established.
The impact on the identification of prostate-specific antigen (PSA) and prostate cancer (PCa)
Patients need to carry out a digital rectal examination, as well as use other methods of investigation of the prostate prior to treatment with dutas and repeat them periodically during treatment to rule out prostate cancer development.
Determination of the concentration of PSA in serum is an important component of screening aimed at identifying prostate cancer. After 6 months of therapy with dutas average serum PSA level is reduced by about 50%. Patients taking dutas should be defined a new basic PSA levels after 6 months of therapy. In the future, it is recommended to regularly monitor PSA levels.
The use of dutas did not affect the diagnostic value of PSA as a marker of prostate cancer. Any confirmed increase in PSA with respect to the least of its value in the treatment of dutas may indicate the development of prostate cancer (particularly prostate cancer with a high degree of differentiation by Gleason score) or nonadherence dutas should be carefully evaluated, even if the PSA levels remain within the normal range for this age group of patients not taking inhibitors of 5α-reductase.
Total PSA level returns to its original value within 6 months after discontinuation of dutas.
The ratio of free to total PSA remains constant even during therapy with dutas. If the determination of the percentage of free PSA fraction is further used to detect prostate cancer in men receiving dutas, correction of this magnitude is not required.
Effect of long-term use of dutas on the development of breast cancer in men
There were no long-term effect of dutas on the development of breast cancer in men.
Prostate cancer and high-grade tumors graduation
In the 4-year study (REDUCE) compared the use of placebo and dutas have 8231 volunteers aged 50 years to 75 years, with a negative biopsy in the presence of prostate cancer and a PSA level of 2.5 ng / ml to 10 ng / ml at the initial examination .
In the study, 6706 patients underwent a needle biopsy of the prostate gland and on the basis of the results determined by the degree of malignancy of prostate cancer Gleason. 1517 patients in the study were diagnosed with prostate cancer. In most cases, as in the dutas group and in the placebo group were diagnosed with well-differentiated prostate cancer (score Gleason 5-6). Differences in the number of prostate cancer cases with the assessment of 7-10 points Gleason in the dutas group and the placebo group were absent (p = 0.81).
4, it was observed more cases of breast cancer with the evaluation 8-10 Gleason dutas group (n = 29; 0.9%) compared with the placebo group (n = 19; 0.6%) (p = 0.15). When evaluating biopsy 1-2, the number of patients diagnosed with prostate cancer with an estimate 8-10 Gleason was comparable in groups dutas (n = 17; 0.5%) or placebo (n = 18; 0.5%). In assessing biopsy for 3-4 years it was diagnosed more cases of prostate cancer with the assessment of 8-10 points Gleason in the dutas group (n = 12; 0.5%) compared with the placebo group (n = 1, <0.1%) (p = 0.0035). The percentage of patients diagnosed with prostate cancer with an estimate 8-10 Gleason was stable during all time slots (the period of 1-2 years, and 3-4) in the group of dutas (0.5% in each period), while in placebo percentage of patients diagnosed with prostate cancer with 8-10 evaluation was lower for 3-4 years, 1-2 years than (<0.1% compared to 0.5% respectively).
In the 4-year study (CombAT) patients with BPH, in which prostate biopsy to all participants has not been determined protocol, and all diagnoses of prostate cancer based on a biopsy if indicated, with evaluation 8-10 prostate cancer Gleason was diagnosed in 8 patients (<0.5%) at dutas, 11 patients (<0.7%) with tamsulosin and 5 patients (<0.3%) in the combination therapy with tamsulosin and dutas.
A causal relationship between dutas and the development of prostate cancer a high degree of gradation is not established.
Men taking dutas should undergo regular examinations for assessing the risk of developing prostate cancer, including a PSA.
Effects on ability to drive vehicles and management mechanisms
dutas does not affect driving or using machinery.
If the kidney function
If the kidney function dose reduction is required (because while taking the drug at a dose of 500 mg / day with urine allocated less than 0.1% of the dose).
If abnormal liver function
It should be used with caution on patients with impaired liver function since dutas undergoes extensive metabolism in the liver, and its T1 / 2 of 3-5 weeks.

Precautions should be prescribed the drug for liver failure.
The use in the elderly

No dose adjustment is required.
Application in childhood
Avodart is contraindicated in children.

02.02.2015 | | Hair Loss, Male health

Comments Off on Buy Dutas online

Buy Propecia (Finasteride) Online

Discount 10%.

>>> Buy now PROPECIA <<<


Active Ingredient: Finasteride
Other names for this medication:
Alopec, Alopros, Alsteride, Ambulase, Andofin, Androfin, Andropel, Andropyl, Androstatin, Antiprost, Apeplus, Aprost, Ativol, Avertex, Borealis, Chibro-proscar,  Daric, Dilaprost,  Eucoprost, Finacapil, Finahair,  Finalop,  Finamed,  Finanorm, Finapil, Finar, Finarid, Finascar, Finaspros, Finaster, Finasterax, Finasterida, Finastéride, Finasteridum, Finasterin, Finastid, Finastir, Finazil, Fincar 5,  Finocar, Finol, Finpro, Finpros, Finprostat,  Finster, Fintex,  Fintral,  Fintrid, Finural, Firide, Fisterid, Fisteride, Fistrin, Flaxin, Flutiamik, Folcres, Folister, Fynasid, Gefina, Genaprost, Glopisine, Hyplafin, Kinscar, Lifin, Lopecia, Mostrafin, Nasteril, Nasterol, Penester, Poruxin, Pro-cure,  Prohair, Proleak, Pronor, Propeshia, Prosmin, Prostacide, Prostacom, Prostafin, Prostanil, Prostanorm, Prostanovag, Prostarinol, Prostasax, Prostene, Prosterid, Prosterit, Prostide, Q-prost, Recur,  Reduprost, Reduscar, Renacidin,  Reprostom, Sterakfin, Sutrico, Symasteride, Tealep, Tensen, Tricofarma, Ulgafen, Urototal, Vetiprost, Winfinas, Zasterid, Zerlon.

Propecia is a medicinal product that belongs to the group of inhibitors of 5-alpha-reductase, used to treat baldness in representatives of the strong half of humanity.

What are the composition and form of the preparation of Propecia?
The active component of the drug Propecia is represented by finasteride, the◦ amount of which is 1 milligram per tablet. Data on excipients of medicament are absent.
Propecia is produced in tablets of pink color, biconvex, rounded. Supplied in polyethylene bottles of 90 and in blisters for 10 pieces. You do not need a doctor’s prescription to◦ buy a medicine.

What means does Propecia have?
Medication Propecia is intended for the treatment of hair loss (alopecia) in the male type. I will clarify that the basis of this disease is the◦ toxic damage of the hair follicles male sex hormone – testosterone. Sometimes you can find the term androgenic and androgenetic alopecia, which is inherently the same disease.

The defeat of the hair follicles is due to the activity of dihydrotestosterone, which is a biologically active form of◦ the male sex hormone.

Finasteride – an active component of the drug, is able to suppress the◦ reactions of biological synthesis of this substance, as well as partially block its effects.

The suppression of dihydrotestosterone inhibits the progression of alopecia, slows the processes underlying hair loss. In some cases, even partial restoration of◦ hair follicles is possible.

The first results of treatment should not be expected too soon. As a rule, at least 3 months must elapse before a noticeable relief of◦ symptoms occurs. The degree of restoration of hair follicles depends on many factors, in particular, on age, the presence of metabolic diseases, bad habits and other factors.

The effect of the drug is short. After the end of treatment, for a certain period, measured by several months, hair loss will inevitably continue.

Information on the◦ rate of absorption of the active substance from the intestine, as well as its distribution in the body is absent.

What are the medicines Propecia indications for use?
Propecia is indicated as an agent for the treatment and prevention of◦ male hair loss. There are no other conditions involving the use of this drug.

Before starting treatment, you should consult a specialist for a comprehensive examination, primarily aimed at determining the level of dihydrotestosterone.

What are the tablets Propecia contraindications for use?
Propecia is contraindicated in the presence of the following conditions:

☞Pregnancy and lactation;
☞Age is less than 12 years;
☞Individual intolerance.

⚠Women should not resort to the use of◦ this medication. In addition, it is strongly recommended during pregnancy to avoid contact with the drug, even given that the active substance of◦ the dosage form is covered with a special coating.

What are Propecia’s use and dosage?
It is usually recommended to take 1 tablet of the drug a day, regardless of food. Do not crush or crush the medicine. If desired, it is acceptable to◦ take the tablet with a small amount of water. It is better to take medication at regular intervals.

As mentioned above, treatment should be of a lasting nature, as a rule, the◦ maximum therapeutic effect develops one year after the start of treatment. For detailed information on the timing of treatment, contact your doctor. Dosage adjustment for patients of◦ the older age group is not required.

Overdose from Propecia
Data on the manifestation of an overdose of the◦ drug Propecia instruction on the application does not lead, because they do not exist. Even taking 8 tablets per day for a long period of time did not lead to any negative symptoms.

However, taking a high dose of medication does not help to increase the therapeutic effect. It is also worth considering the rather high cost of a single package of a drug.

What are the side effects of Propecia?
In most cases, taking the medication is not accompanied by the◦ development of undesirable consequences. Nevertheless, in some cases, the following symptoms can not be avoided: a decrease in libido (level of sexual desire), erectile dysfunction, a decrease in the volume of ejaculate, allergic manifestations in the◦ form of itching, swelling of the face, tenderness in the testicles.

Special instructions
With the simultaneous administration of drugs used to treat prostatitis, for example, Proscar or its analogues, it is possible to enhance the◦ effect of the latter and increase the incidence of side effects. In most cases, a separate specialist consultation will be required.

To treat hair loss should follow a comprehensive campaign. To begin with, it is necessary to exclude any diseases that, one way or another, can lead to the◦ development of such symptoms. In addition, one should not write off the◦ importance of rational nutrition, the rejection of bad habits, the fight against stress.

In addition, combined methods of treatment, suggesting the use of drugs like Propecia, as well as the use of◦ ointment, cream and gel, are well proven.

The patient should be instructed to use the prescribed medication alone. Be healthy!

Buy Propecia (Finasteride).

⚤Categories ☟

Recent Comments

error: Content is protected !!